License, Collaborative and Employment Agreements and Commitments (Details Textual) - USD ($)			1 Months Ended						12 Months Ended
	Dec. 04, 2015	Aug. 10, 2015	Aug. 31, 2015	Aug. 29, 2015	Aug. 10, 2015	Apr. 28, 2015	Mar. 18, 2015	Feb. 29, 2012	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
License, Collaborative and Employment Agreements and Commitments [Line Items]
Research and Development Expense									$ 32,906,000	$ 14,489,000	$ 6,507,000
Operating Leases, Rent Expense									108,000	77,000	68,000
Operating Leases, Future Minimum Payments Due, Next Twelve Months									148,000
Prepaid Expense and Other Assets, Current									9,519,000	1,548,000
Payments to Acquire in Process Research and Development									$ 424,000	$ 293,000	$ 1,000,000
Exchange percentage of unregistered common stock									50.00%
Proceeds from (Repurchase of) Equity, Total									$ 3,000,000
Stock Purchase Agreement [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Conversion of Stock, Shares Converted				1,350,000
Conversion of Stock, Shares Issued			1,350,000	1,350,000
Channel Collaboration Agreement [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Shares, Issued		937,500			937,500
Stock Issued		$ 3,000,000			$ 3,000,000
Mark Pimentel [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Common stock Outstanding Percentage									8.50%
Licensing Agreements [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Payments for Fees									$ 150,000
Stock Issued During Period, Shares, New Issues									334,911
Patents [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Payments for Fees									$ 220,000
Riley Employment Agreement [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense	$ 550,000						$ 385,000
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage							75.00%
Shallcross Employment Agreement [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value									1,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						900,000
Deferred Compensation Arrangement with Individual, Compensation Expense						$ 315,000
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage						75.00%
Deferred Compensation Arrangement with Individual, Maximum Contractual Term						2 years
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent						50.00%
Ballantyne Employment Agreement [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense							$ 335,000
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage							75.00%
Jeffrey Riley [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value								$ 1,700,000
Officers Compensation								$ 348,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								750,000
C. Evan Ballantyne [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value								$ 1,000,000
Officers Compensation								$ 298,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								425,000
Intrexon [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Research and Development Expense												$ 7,800,000
Milestone Payment		27,000,000
Stock Issued During Period, Shares, Acquisitions												3,552,210
Prepaid Expense and Other Assets, Current									2,500,000
Shares Issued, Price Per Share												$ 0.001
Milestone Payment upon First Dosing		$ 2,000,000
Intrexon [Member] | Minimum [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Royalty Revenue, Total									100,000,000
Intrexon [Member] | Maximum [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Royalty Revenue, Total									750,000,000
Intrexon [Member] | Research and Development Arrangement [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Prepaid Expense and Other Assets, Current									$ 643,000
Prev Abr Llc [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Additional Cash Payment for License Agreement												$ 235,000
Unregistered Shares Issued to License Agreement												625,000
Additional Consideration Payable												50% in cash and 50% in our stock
Options To Be Received Common Stock Shares									655,321
Cedars-Sinai Medical Center [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Common stock Outstanding Percentage									11.50%
Office Space In Ann Arbor [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Operating Lease Leasing Term												extend the term of the lease to December 31, 2016
Operating Leases, Future Minimum Payments Due, Next Twelve Months												$ 40,000
Office Space In Rockville [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Operating Lease Leasing Term												sixty-six month operating lease that may be renewed for one additional term of five years
Operating Annual Lease Payments												$ 142,172
December 31, 2014 [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Operating Leases, Future Minimum Payments Due, Next Twelve Months												50,000
December 31, 2015 [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Operating Leases, Future Minimum Payments Due, Next Twelve Months												25,000
Phase I Clinical Trials [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Milestone Payment												50,000
Phase III Clinical Trials [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Milestone Payment												100,000
NDA Submission In US [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Milestone Payment												250,000
European Medicines Agency Approval [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Milestone Payment												100,000
Regulatory Approval In Asian Country [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Milestone Payment												$ 100,000
IND Milestone Event [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Registration Payment Arrangement, Settlement Alternatives												The Company also agreed upon the filing of an IND application with the FDA for a Synthetic Product, or alternatively the filing of the first equivalent regulatory filing with a foreign regulatory agency (both as applicable, the IND Milestone Event), to pay Intrexon either (i) $2.0 million in cash, or (ii) that number of shares of Common Stock (the IND Milestone Shares) having a fair market value equaling $2.0 million where such fair market value is determined using published market data of the share price for Common Stock at the close of market on the business day immediately preceding the date of public announcement of attainment of the IND Milestone Event.
Approval Milestone Event [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Registration Payment Arrangement, Settlement Alternatives												Upon the first to occur of either first commercial sale of a Synthetic Product in a country or the granting of the regulatory approval of that Synthetic Product (both as applicable, the Approval Milestone Event), the Company agreed to pay to Intrexon either (i) $3.0 million in cash, or (ii) that number of shares of Common Stock (the Approval Milestone Shares) having a fair market value equaling $3.0 million where such fair market value is determined using published market data of the share price for Common Stock at the close of market on the business day immediately preceding the date of public announcement of attainment of the Approval Milestone Event.
Field Expansion Fee [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Registration Payment Arrangement, Settlement Alternatives												The Field Expansion Fee must be paid completely in either Common Stock or cash, and will comprise either (i) $2.0 million in cash for each target in excess of three total that the Company elects, or (ii) that number of shares of Common Stock (the Field Expansion Fee Shares) having a fair market value equaling $2.0 million for each such target that the Company elects in excess of three where such fair market value is determined using published market data establishing the volume-weighted average price for a share of Common Stock over the 30 day period immediately preceding the date of the Field Expansion Fee Closing.
First Year [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Research Agreement Fixed Fee									$ 303,287
Second Year [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Research Agreement Fixed Fee									316,438
Third Year [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Research Agreement Fixed Fee									$ 328,758